Effects of Salbutamol on the Treatment of Transient Tachypnea of the Newborn

Document Type : Original Article


1 Department of Pediatrics, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

2 Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran


Background: This study aimed to evaluate the safety and efficacy of inhaled salbutamol for the treatment of Transient Tachypnea of the Newborn (TTN).
Methods: Totally, 80 neonates with TTN were randomly assigned into two groups of treatment and placebo. The treatment and placebo groups received one dose of nebulized salbutamol (dose of 0.15 ml/kg in 2 ml of normal saline) and only 2 ml 0.9% normal saline without salbutamol, respectively. Before starting the study and30, 60 min, and 4 h after nebulization, the respiratory and heart rates, oxygen saturation, a fraction of inspired oxygen, respiratory distress score, the arterial blood gas(after 4 hours), and the time of hospital stay evaluated. The data were analyzed in SPSS software (version 23) through Fisher's exact test, Mann-Whitney U test, and ANOVA.
Results: There were no significant differences between the case and control groups with regard to gender, gestational age, birth weight, mother's history of asthma, type of delivery, first-and fifth-minute Apgar, pneumothorax, and respiratory rates. The duration of tachypnea, hospital stay, oxygen therapy, and the time of initiating enteral feeding were shorter in the case group compared to the control group.
Conclusion: The administration of the salbutamol can significantly improve respiratory distress following 4 h and reduce the duration of hospital stay, tachypnea, and the time of enteral feeding.


1. Avery ME, Gatewood OB, Brumley G. Transient tachypnea of newborn. Possible delayed resorption of fluid at birth. Am J Dis Children. 1966; 111(4): 380-5.
2. Crowley MA. Neonatal respiratory disorders. In: Martin RJ, Fanaroff AA, Walsh MC, editors. Fanaroff and Martin's neonatal-perinatal medicine: diseases of the fetus and infant. 10th ed. St. Louis: Elsevier Mosby; 2015. P. 1113-33.
3. Clark RH. The epidemiology of respiratory failure in neonates born at an estimated gestational age of 34 weeks or more. J Perinatol. 2005; 25(4):251-7.
4. Takaya A, Igarashi M, Nakajima M, Miyake H, Shima Y, Suzuki S. Risk factors for transient tachypnea of the newborn in infants delivered vaginally at 37 weeks or later. J Nippon Med Sch. 2008; 75(5): 269-73.
5. Lewis V, Whitelaw A. Furosemide for transient tachypnea of the newborn. Cochrane Database Syst Rev. 2002; 1:CD003064.
 6. Jain L, Eaton DC. Physiology of fetal lung fluid clearance and the effect of labor. Semin Perinatol. 2006; 30:34-43.
7. Richardson BS, Czikk MJ, daSilva O, Natale R. The impact of labor at term on measures of neonatal outcome. Am J Obstet Gynecol. 2005; 192(1):219-26.
8. Zanardo V, Simbi AK, Franzoi M, Soldà G, Salvadori A, Trevisanuto D. Neonatal respiratory morbidity risk and mode of delivery at term: influence of timing of elective caesarean delivery. Acta Paediatr. 2004; 93(5):643-7.
9. Sakuma T, Tuchihara C, Ishigaki M, Osanai K, Nambu Y, Toga H, et al. Denopamine, a beta (1)-adrenergic agonist, increases alveolar fluid clearance in ex vivo rat and guinea pig lungs. J Appl Physiol. 2001; 90(1):10-6.
 10. Sakuma T, Folkesson HG, Suzuki S, Okaniwa G, Fujimura S, Matthay MA. Beta-adrenergic agonist stimulated alveolar fluid clearance in ex vivo human and rat lungs. Am J Respir Crit Care Med. 1997; 155(2):506-12.
11. Mutlu GM, Factor P. Alveolar epithelial beta2- adrenergic receptors. Am J Respir Cell Mol Biol. 2008; 38(2):127-34.
 12. Irestedt L, Lagercrantz H, Hjemdahl P, Hägnevik K, Belfrage P. Fetal and maternal plasma catecholamine levels at elective cesarean section under general or epidural anesthesia versus vaginal delivery. Am J Obstet Gynecol. 1982; 142(8):1004-10.
13. Ronca AE, Abel RA, Ronan PJ, Renner KJ, Alberts JR. Effects of labor contractions on catecholamine release and breathing frequency in newborn rats. Behav Neurosci. 2006; 120(6):1308-14.
14. Smith DE, Otulakowski G, Yeger H, Post M, Cutz E, O'Brodovich HM. Epithelial Na(+) channel (ENaC) expression in the developing normal and abnormal human perinatal lung. Am J Respir Crit Care Med. 2000; 161(4 Pt 1):1322-31.
15. Armangil D, Yurdakök M, Korkmaz A, Yiğit Ş, Tekinalp G. Inhaled beta-2 agonist salbutamol for the treatment of transient tachypnea of the newborn. J Pediatr. 2011; 159(3):398-403.
 16. Kim MJ, Yoo JH, Jung JA, Byun SY. The effects of inhaled albuterol in transient tachypnea of the newborn. Allergy Asthma Immunol Res. 2014; 6(2):126-30.
17. Kao B, Stewart de Ramirez S, Belfort MB, Hansen A. Inhaled epinephrine for the treatment of transient tachypnea of the newborn. J Perinatol. 2008; 28(3):205-10.
 18. Moresco L, Bruschettini M, Cohen A, Gaiero A, Calevo MG. Salbutamol for transient tachypnea of the newborn. Cochrane Library. 2016; 5:CD011878.
19. Guglani L, Lakshminrusimha S, Ryan RM. Transient tachypnea of the newborn. Pediatr Rev. 2008; 29(11):59-65.
20. Harding R, Hooper SB. Regulation of lung expansion and lung growth before birth. J Appl Physiol. 1996; 81(1):209-24.
21. Mohammadzadeh I, Akbarian-Rad Z, Heidari F, Zahedpasha Y, Haghshenas-Mojaveri M. et al. The effect of inhaled salbutamol in transient of tachypnea of the newborn: a randomized clinical trial. Iran J Pediatr. 2017; 27(5):e9633.
22. Mussavi M, Asadollahi K, Kayvan M, Sadeghvand S. Effects of nebulized albuterol in transient tachypnea of the newborn a clinical trial. Iran J Pediatr. 2017; 27(3):e8211.